Pneumococcal Vaccine Market – By Product, By Vaccine Type, By Age Group, By Distribution Channel – Global Forecast, 2025 – 2034

Pneumococcal Vaccine Market Size

The global pneumococcal vaccine market was valued at USD 8.8 billion in 2024. The market is expected to grow from USD 9.2 billion in 2025 to USD 15.1 billion in 2034, at a CAGR of 5.6%. The increasing number of target diseases, increased awareness, supportive government policies, and rising research and development for manufacturing innovative vaccines are the most significant drivers of market growth.
 

According to the World Health Organization (WHO), in 2023, it was estimated that around 1.6 million individuals die annually due to pneumococcal disease, among which almost 1 million are children under the age of five. Also, WHO places immunization of pneumococcal disease in children as a top priority and recommends the use of 13-valent conjugate vaccines.
 

The market is expected to grow tremendously with the regulatory approval and introduction of new pneumococcal vaccines. For instance, in April 2023, Pfizer's PREVNAR 20, a 20-valent pneumococcal conjugate vaccine, received approval from the FDA for use in preventing invasive pneumococcal disease in infants and children aged 6 weeks to 17 years, and otitis media in infants 6 weeks to 5 years. Alongside this development, Sanofi and SK Bioscience presented promising phase II clinical trial results with their 21-valent conjugate vaccine GBP410 in June 2023, which is anticipated to gain substantial adoption over existing vaccines. These two companies are planned to advance to phase III in 2024 based on the latest data by 2027.
 

Furthermore, increased awareness and favorable government policies are also driving the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in 2022, the United States Department of Health and Human Services had established objectives for the Healthy People 2030 program to raise adult immunization levels (19 years and older). One of the major objectives among them was encouraging pneumococcal vaccination, which had proven effective against such infections. The general objective was to surpass a vaccination rate of 90% for Advisory Committee on Immunization Practices-recommended vaccines.
 

Pneumococcal Vaccine Market Trends

• Higher-valent vaccines such as PCV15 and PCV20 are being increasingly used to provide broader serotype protection and enhanced pneumococcal protection. These vaccine types are also under development by various market players.
   
• Governments and health professionals are now focusing more on adult immunization schemes, especially among the elderly and vulnerable populations, thereby generating an increasing demand for pneumococcal vaccines among them.
   
• For instance, in September 2023, the Centers for Disease Control and Prevention (CDC) increasingly promoted the use of pneumococcal vaccines, targeting adults 65 years and above, regarding the usage of pneumococcal vaccines with regards to adults above 65 years of age along with other people with specified medical conditions predisposing them to the disease. These initiatives were aimed at spreading awareness and advancing vaccination programs, promoting a shift in the traditional market paradigm.
   
• Additionally, there is increasing interest in the creation of combination vaccines that can protect against numerous diseases, such as pneumococcal-Hib vaccines, to decrease the schedule of immunization and increase the coverage level.
   

Pneumococcal Vaccine Market Analysis

Based on product, the market is segmented into Pneumosil (PCV10), Pneumovax 23 (PPSV23), Prevnar 13 (PCV13), Prevnar 20 (PCV20), Synflorix (PCV10), Vaxneuvance (PCV15), and other products. The Prevnar 13 (PCV13) segment is expected to drive business growth and expand at a CAGR of 5.8%, reaching over USD 7.9 billion by 2034.
 

• Prevnar 13 is a 13-valent pneumococcal conjugate vaccine that offers protection against 13 Streptococcus pneumoniae serotypes and is, hence, very effective against pneumococcal diseases such as pneumonia, meningitis, and sepsis, promoting its extensive usage.
   
• Prevnar 13 was one of the initial pneumococcal conjugate vaccines and has an established safety and efficacy profile, generating an enormous level of confidence among healthcare providers and patients.
   
• Additionally, global institutions like Gavi, UNICEF, WHO, and the Gates Foundation make it easier for middle- and low-income countries (LMICs) to receive Prevnar 13, which increases its availability and use worldwide.
   

Based on vaccine type, the pneumococcal vaccine market is bifurcated into pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV). The pneumococcal conjugate vaccines (PCV) segment generated revenue of USD 8 billion in 2024.
 

• The increasing incidence of pneumococcal infections, including sepsis, meningitis, and pneumonia, is one of the major contributing factors to the high mortality and morbidity rate among children aged 5 years and below. For instance, according to the National Institutes of Health (NIH), globally, each year approximately 150 million new cases of pneumonia are diagnosed among children aged below 5 years. This high volume of new diagnoses and its high fatality risk is driving the demand for effective vaccination, facilitating the segment growth.
   
• Additionally, the increasing use of PCVs among adult populations, especially immunocompromised people and older adults, is significantly driving the demand for vaccination.
   

Based on age group, the pneumococcal vaccine market is segmented into infants and children (0–5 years), adults (18–64 years), and elderly (65+ years). The infants and children (0-5 years) segment generated a revenue of USD 5.4 billion in 2024.
 

• The growing burden of diseases, such as meningitis, pneumonia, and sepsis, is driving the demand for pneumococcal vaccination among children between 0 to 5 years. For instance, according to UNICEF, pneumonia is the cause of fatality in approximately 700,000 children under the age of 5 each year. This high fatality rate has highlighted the growing need for vaccination initiatives in this age group, facilitating the segment growth.
   
• Additionally, various global initiatives, such as the Sustainable Development Goals (SDGs) by the United nations, place emphasis on the pneumonia therapeutics among young children through widespread vaccination programs, thereby driving the segment growth.
   

Based on distribution channel, the pneumococcal vaccine market is segmented into hospital pharmacies, retail pharmacies, government and public health agencies, and e-commerce. The government and public health agencies segment generated revenue of USD 5 billion in 2024.
 

• The adoption and initiation of national immunization programs by different governments for subsidized or free pneumococcal vaccines to at-risk vulnerable children, infants, and others is propelling the segment growth.
   
• Additionally, international bodies like UNICEF, WHO, and the Vaccine Alliance, Gavi also provides subsidized logistical, technical, and financial aid for pneumococcal vaccination programs in middle and lower income countries, thus increasing the segment growth.
   

North America: The U.S. pneumococcal vaccine market was valued at USD 3.7 billion in 2024 and is projected to grow substantially in the coming years.
 

• The U.S. has a rapidly increasing elderly population, having a high risk of contracting pneumococcal conditions due to their weakened immuno-capabilities. For instance, according to the Administration for Community Living (ACL), there were approximately 57.8 million U.S. individuals aged 65 years and above in 2022. This high volume of elderly population has prompted the demand for pneumococcal vaccination, thereby driving market growth in the region.
   
• Additionally, initiatives by various government and national organizations such as the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC), that strongly recommend pneumococcal vaccination among immunocompromised people, older adults, and children, are further driving market growth.
   

Europe: UK pneumococcal vaccine market is projected to grow remarkably in the coming years.
 

• The rising antimicrobial resistance (AMR) in the UK emphasizes the focus on vaccination as a preventive measure. The UK government policy on AMR emphasizes the role of vaccinations like pneumococcal immunization in minimizing bacterial infection, minimizing the use of antibiotics, and combating resistance.
   
• Additionally, government organizations such as the UK National Health Service (NHS) offer free pneumococcal vaccination under the universal immunization program, covering babies, adults aged 65 years and older, and people with certain medical conditions. The government's investment in vaccination as a disease control measure through prevention makes it readily accessible and encourages uptake among all the targeted groups, thereby driving market growth in the region.
   

China holds a dominant position in the Asia Pacific pneumococcal vaccine market.
 

• China's expanding middle-class consumers and rising disposable incomes have meant greater demand for preventive healthcare, including immunization. Parents are now more than willing to spend extra on vaccines such as pneumococcal immunization to protect their children, and people are proactively disease-conscious, particularly following the COVID-19 pandemic.
   
• Additionally, China possesses one of the world's highest rates of antibiotic use, the basis of mounting concerns about antimicrobial resistance (AMR). Vaccines were recognized by the government as a key component to avoid bacterial infection and the excessive use of antibiotics. Pneumococcal vaccination is also being recognized increasingly as a crucial measure in averting AMR, thereby driving market growth in the region.
   

Saudi Arabia in the Middle East and Africa is expected to witness lucrative growth in the pneumococcal vaccine market.
 

• Recommendation of pneumococcal vaccination among children under the age of 5 years, adults aged 50 and above, and individuals with specific risk factors aged 6 years and above by Saudi Thoracic Society is driving the revenue growth in the country.
   
• Further, in February 2024, Saudi Arabia approved 15-valent pneumococcal conjugate vaccine (PCV15) for use across pediatric patients, offering expanded coverage for serotype in comparison to PCV13. Approval and easy availability of new and improved pneumococcal treatment is aiding to the revenue growth in the Saudi Arabia.
   

Pneumococcal Vaccine Market Share

The market is concentrated, featuring 7 pharmaceutical firms having approved products. The top players in this market include Pfizer, GlaxoSmithKline, and Merck & Co., which account for approximately 60% of the market share. These players are constantly investing in the development of advanced vaccines to enhance disease prevention.
 

Moreover, strategic partnerships with research institutions and healthcare providers have become critical for integrating modern technologies and expanding distribution, which has enabled the companies to address the surge in demand for treatment options. Owing to regulatory support and streamlined approval processes, which further motivate innovation and facilitate market entry, contribute to increased competition in the market. Emerging players are focusing on the development of new treatments that aim to improve disease management. These innovations continue to promote market progression.
 

Pneumococcal Vaccine Market Companies

Prominent players operating in the pneumococcal vaccine industry include:

• Beijing Minhai Biological Technology
• Bio-Manguinhos/Fiocruz
• GlaxoSmithKline
• Merck & Co.
• Pfizer
• Serum Institute of India
• Walvax Biotechnology
   
• Pfizer is a major and dominant player in the market. The company has captured a significant market share through its Prevnar 13 (PCV13) conjugate vaccine, which is highly popular and has an extensive global reach. Additionally, through its strong and advanced research and development capabilities the company introduced Prevnar 20 (PCV20), covering a broad serotype and offering enhanced protection.
   
• GSK is another important player in the market of pneumococcal vaccines. Through its collaborations with global organizations such as Gavi, and a predominant focus on sustainability, GSK has built an extensive distribution network to ensure that its vaccines are delivered even to the remotest location of the world. It’s Synflorix (PCV10) vaccine is a popular pneumococcal vaccine, particularly across the developing countries.
   
• Merck & Co. offers broad serotype coverage and adult focused vaccine design, which targets the serotypes that are more common in adults, through its CAPVAXIVE. The efficacy of the vaccine is also supported by positive results across several clinical studies.
   

Pneumococcal Vaccine Industry News:

• In April 2023, Pfizer announced the approval of its PREVNAR 20, a 20-valent pneumococcal conjugate vaccine, by the U.S. Food and Drug Administration (FDA), indicated for the prevention of invasive pneumococcal disease in children aged between six weeks and 17 years. The vaccine was also indicated for use in children aged between six weeks and five years for the prevention of otitis media. This approval significantly expanded the company’s existing dominant position in the market.
   
• In May 2022, GlaxoSmithKline announced the acquisition of Affinivax, Inc., a biopharmaceutical company engaged in the development of novel vaccines including next-generation pneumococcal vaccines. The acquisition was expected to broaden the company’s vaccine portfolio and provide more options for patients affected by pneumococcal conditions.
   
• In June 2024, Merck & Co. announced the approval of its CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine, by the U.S. FDA. The vaccine was indicated for immunization against invasive pneumococcal disease among patients aged 18 years and over. This approval enabled the company to introduce novel immunization options for supplementing the growing pneumococcal vaccine demand.
   

The pneumococcal vaccine market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Pneumosil (PCV10)
• Pneumovax 23 (PPSV23)
• Prevnar 13 (PCV13)
• Prevnar 20 (PCV20)
• Synflorix (PCV10)
• Vaxneuvance (PCV15)
• Other products

Market, By Vaccine Type

• Pneumococcal conjugate vaccines (PCV)
• Pneumococcal polysaccharide vaccines (PPSV)

Market, By Age Group

• Infants and children (0–5 years)
• Adults (18–64 years)
• Elderly (65+ years)

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Government and public health agencies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE